Synergistic cytokine effects as apremilast response predictors in patients with psoriasis

被引：25
作者：
Garcet, Sandra [1 ]
Nograles, Kristine [2 ]
da Rosa, Joel Correa [1 ]
Schafer, Peter H. [3 ]
Krueger, James G. [1 ]
机构：
[1] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA
[2] Celgene Corp, Clin Res & Dev, Summit, NJ USA
[3] Celgene Corp, Dept Translat Dev, Summit, NJ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2018年 / 142卷 / 03期
关键词：
SEVERE PLAQUE PSORIASIS; PHOSPHODIESTERASE-4; INHIBITOR; PDE4; PHASE-III; EFFICACY; MODERATE; SAFETY;
D O I：
10.1016/j.jaci.2018.05.039
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：1010 / 1013
页数：5
相关论文
共 9 条
[1]   Cytokines in psoriasis [J].
Baliwag, Jaymie ;
Barnes, Drew H. ;
Johnston, Andrew .
CYTOKINE, 2015, 73 (02) :342-350
[2]   Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis [J].
Chiricozzi, Andrea ;
Guttman-Yassky, Emma ;
Suarez-Farinas, Mayte ;
Nograles, Kristine E. ;
Tian, Suyan ;
Cardinale, Irma ;
Chimenti, Sergio ;
Krueger, James G. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (03) :677-687
[3]   Immunology of Psoriasis [J].
Lowes, Michelle A. ;
Suarez-Farinas, Mayte ;
Krueger, James G. .
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32, 2014, 32 :227-255
[4]   Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) [J].
Papp, Kim ;
Reich, Kristian ;
Leonardi, Craig L. ;
Kircik, Leon ;
Chimenti, Sergio ;
Langley, Richard G. B. ;
Hu, ChiaChi ;
Stevens, Randall M. ;
Day, Robert M. ;
Gordon, Kenneth B. ;
Korman, Neil J. ;
Griffiths, Christopher E. M. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) :37-49
[5]   Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) [J].
Paul, C. ;
Cather, J. ;
Gooderham, M. ;
Poulin, Y. ;
Mrowietz, U. ;
Ferrandiz, C. ;
Crowley, J. ;
Hu, C. ;
Stevens, R. M. ;
Shah, K. ;
Day, R. M. ;
Girolomoni, G. ;
Gottlieb, A. B. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) :1387-1399
[6]   Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity [J].
Schafer, P. H. ;
Parton, A. ;
Capone, L. ;
Cedzik, D. ;
Brady, H. ;
Evans, J. F. ;
Man, H. -W. ;
Muller, G. W. ;
Stirling, D. I. ;
Chopra, R. .
CELLULAR SIGNALLING, 2014, 26 (09) :2016-2029
[7]   Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis [J].
Schafer, P. H. ;
Parton, A. ;
Gandhi, A. K. ;
Capone, L. ;
Adams, M. ;
Wu, L. ;
Bartlett, J. B. ;
Loveland, M. A. ;
Gilhar, A. ;
Cheung, Y-F ;
Baillie, G. S. ;
Houslay, M. D. ;
Man, H-W ;
Muller, G. W. ;
Stirling, D. I. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (04) :842-855
[8]   Apremilast mechanism of action and application to psoriasis and psoriatic arthritis [J].
Schafer, Peter .
BIOCHEMICAL PHARMACOLOGY, 2012, 83 (12) :1583-1590
[9]   The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1) [J].
Schafer, Peter H. ;
Chen, Peng ;
Fang, Lorraine ;
Wang, Andrew ;
Chopra, Rajesh .
JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
1